Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.

MLA

Lazzari, Elisa de, et al. “Multiomics Plasma Effects of Switching from Triple Antiretroviral Regimens to Dolutegravir plus Lamivudine.” Journal of Antimicrobial Chemotherapy (JAC), vol. 79, no. 5, May 2024, pp. 1133–41. EBSCOhost, https://doi.org/10.1093/jac/dkae083.

APA

Lazzari, E. de, Negredo, E. B., Domingo, P., Tiraboschi, J. M., Ribera, E., Abdulghani, N., Alba, V., Fernández-Arroyo, S., Viladés, C., Peraire, J., Gatell, J. M., Blanco, J. L., Vidal, F., Rull, A., & Martinez, E. (2024). Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. Journal of Antimicrobial Chemotherapy (JAC), 79(5), 1133–1141. https://doi.org/10.1093/jac/dkae083

Chicago

Lazzari, Elisa de, Eugenia B Negredo, Pere Domingo, Juan M Tiraboschi, Esteve Ribera, Nadia Abdulghani, Verònica Alba, et al. 2024. “Multiomics Plasma Effects of Switching from Triple Antiretroviral Regimens to Dolutegravir plus Lamivudine.” Journal of Antimicrobial Chemotherapy (JAC) 79 (5): 1133–41. doi:10.1093/jac/dkae083.